Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only.All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

2X Blend_CJC-1295 No DAC Ipamorelin_5MG

2X Blend (CJC-1295 + Ipamorelin)

2X Blend is a research-grade peptide formulation combining CJC-1295 (No DAC), a short-acting growth hormone–releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue. This blend is designed for laboratory research focused on endogenous growth hormone (GH) pulsatility, peptide synergy, and somatotropic axis signaling without direct GH administration.*

Unlike DAC-modified versions, CJC-1295 No DAC retains a short biological activity profile similar to native GHRH, making it suitable for research investigating natural GH pulse timing and feedback regulation.* Ipamorelin complements this mechanism through selective ghrelin receptor (GHS-R) activation with minimal involvement of cortisol or prolactin pathways.*

Together, these peptides are commonly referenced in experimental research exploring coordinated endocrine signaling and receptor-mediated GH release dynamics.*

  • Peptide Components:
    • 5mg CJC-1295 (No DAC) – GHRH analog
    • 5mg Ipamorelin – Ghrelin receptor agonist
  • Peptide Class: Growth hormone secretagogues (GHS)
  • Form: Lyophilized powder
  • Purity: ≥99% (HPLC verified)
  • Total Quantity: 10 mg per vial (combined blend)
  • Analytical Verification: HPLC and Mass Spectrometry (MS)
  • Manufacturing: Solid-phase peptide synthesis with in-house purification
  • Designation: For Research Use Only (RUO)

$80.00

$76.00 each
$72.00 each

Products will arrive in a lyophilized (powder) form for maximum stability.

Free domestic shipping on orders over $300

2X Blend (CJC-1295 + Ipamorelin)

Scientific & Research Context

The combination of CJC-1295 No DAC and Ipamorelin has been utilized in scientific literature to investigate pulsatile growth hormone release, endocrine feedback mechanisms, and peptide-receptor interactions within the somatotropic axis.*

In controlled research environments, this blend has been explored for studying:*

  • Synergistic stimulation of endogenous GH secretion*
  • Short-acting GHRH signaling and GH pulse physiology*
  • Regulation of IGF-1 signaling pathways in experimental models*
  • Comparative effects of combined GHRH and GHS receptor activation*
  • Endocrine rhythm modulation without prolonged receptor occupancy*

The short-acting nature of CJC-1295 No DAC, paired with Ipamorelin’s receptor selectivity, makes this blend a valuable research tool in endocrinology, peptide pharmacology, and molecular signaling studies.*

Quality & Analytical Assurance

Each batch of 2X Blend undergoes comprehensive quality control testing to confirm molecular identity, sequence integrity, and purity. Verification using validated HPLC and mass spectrometry methodologies ensures batch-to-batch consistency, reproducibility, and reliability for research applications.

Storage & Handling

2X Blend is supplied in lyophilized form to maintain stability during storage and transport. Store unopened vials in a cool, dry environment protected from light. Reconstitution and handling should follow standard peptide laboratory best practices to preserve molecular integrity and experimental consistency.

For further information on proper storage techniques, click the button…

Storage Instructions

Referenced Scientific Literature
Provided for informational and educational purposes only

  • Raun, K. et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology, 1998; 139(5): 552–561.
  • Andersen, N. B. et al. “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.” Growth Hormone & IGF Research, 2001; 11(5): 266–272.
  • Svensson, J. et al. “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.” Journal of Endocrinology, 2000; 165(3): 569–577.
  • Adeghate, E., and A. S. Ponery. “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats.” Neuroendocrinology Letters, 2004; 25(6): 403–406.
  • Beck, D. E. et al. “Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.” International Journal of Colorectal Disease, 2014; 29(12): 1527–1534.
  • Greenwood-Van Meerveld, B. et al. “Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.” Journal of Experimental Pharmacology, 2012; 4: 149–165.
  • Alba, M. et al. “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.” American Journal of Physiology – Endocrinology and Metabolism, 2006; 291(6): E1290–E1294.
  • Ionescu, M., and L. A. Frohman. “Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog.” Journal of Clinical Endocrinology & Metabolism, 2006; 91(12): 4792–4797.
  • Van Hout, M. C., and E. Hearne. “Netnography of female use of the synthetic growth hormone CJC-1295: Pulses and potions.” Substance Use & Misuse, 2016; 51(1): 73–84.
  • Jetté, L. et al. “hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long-lasting GRF analog.” Endocrine Society / ResearchGate, 2005.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.